Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Zymeworks ( (ZYME) ) just unveiled an announcement.
Zymeworks Inc. announced it will report its fourth quarter and full year 2024 financial results on March 5, 2025, followed by a conference call to discuss the results and provide a corporate update. This announcement signifies the company’s ongoing commitment to transparency and stakeholder engagement while highlighting its strategic advancements in developing novel therapeutics and expanding its presence in the biotechnology industry.
More about Zymeworks
Zymeworks Inc. is a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics aimed at improving treatments for difficult-to-treat diseases such as cancer, inflammation, and autoimmune disorders. The company leverages its therapeutic platforms and drug development engine to engineer antibody-based therapies, including the FDA-approved zanidatamab for HER2-positive biliary tract cancer, and is engaged in multiple global strategic partnerships.
YTD Price Performance: -3.25%
Average Trading Volume: 456,287
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $993.1M
Learn more about ZYME stock on TipRanks’ Stock Analysis page.
